TREATMENT OF HBEAG-POSITIVE CHB INFECTION WITH PEGINTERFERON ALFA-2A [40KD] PLUS LAMIVUDINE OR ADEFOVIR FOR 96 WEEKS RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION

被引：0
|
作者：
Cao, Zhenhuan [1 ]
Zhang, Yonghong [1 ]
Ma, Lina [1 ]
Jin, Yi [1 ]
Yu, Haibin [1 ]
Zhang, Xiao-dan [1 ]
Liu, Yali [1 ]
Huang, Yanxiang [1 ]
Ma, Bing [1 ]
Ren, Shan [1 ]
Wang, Lilin [1 ]
Chen, Xin-Yue [1 ]
Wei, Lai [1 ]
机构：
[1] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
377
引用
收藏
页码：507A / 507A
页数：1
相关论文
共 50 条
  • [31] CHANGES IN HBEAG LEVELS AMONG PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A [40KD] ENROLLED IN THE S-COLLATE COHORT STUDY
    Lou, GuoQiang
    Marcellin, Patrick
    Xie, Yao
    Chen, Xiao P.
    Chen, Yong-Ping
    Rothe, Vivien
    Regep, Loredana
    Martins, Eduardo B.
    Jia, Jidong
    Wei, Lai
    HEPATOLOGY, 2010, 52 (04) : 537A - 537A
  • [32] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [33] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
  • [34] IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24
    Piratvisuth, T.
    Chan, H. L. Y.
    Marcellin, P.
    Wat, C.
    Regep, L.
    Messinger, D.
    Kapprell, H. -P.
    Lu, Z. M.
    Luo, K. X.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S213 - S214
  • [35] Hepatitis B virus (HBV) genotypes:: Distribution and variation in response to treatment with conventional interferon and peginterferon alfa-2A (40KD) (pegasys®) in HBeAg-positive chronic hepatitis b
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, F
    Pluck, N
    HEPATOLOGY, 2002, 36 (04) : 636A - 636A
  • [36] ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy.
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2003, 38 (04) : 724A - 724A
  • [37] Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)
    Piratvisuth, T.
    Lau, G. K. K.
    Marcellin, P.
    Chow, W. C.
    Cooksley, G.
    Fried, M. W.
    Paik, S. W.
    Liaw, Y. F.
    Popescu, M.
    Button, P.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S23 - S23
  • [38] EXTENDING PEGINTERFERON ALFA-2A THERAPY IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B WHO DID NOT ACHIEVE A RESPONSE AT WEEK 48 CAN LEAD TO HBEAG SEROCONVERSION AND HBSAG CLEARANCE
    Chen, Xiao P.
    Chen, Xue-Fu
    Huang, Ji
    Chen, Wen-Li
    Ren, Chen
    Ma, Xiao-jun
    Luo, X-d
    HEPATOLOGY, 2009, 50 (04) : 499A - 499A
  • [39] HIGHER SUSTAINED POST-TREATMENT VIROLOGIC RESPONSE FOLLOWING PEGINTERFERON ALFA-2A ± ADEFOVIR COMPARED WITH ADEFOVIR MONOTHERAPY IN HBEAG-POSITIVE PATIENTS
    Ma, Wei-min
    Zhou, Bo-ping
    Ao, Fei-Jian
    Zhou, Do-qiao
    Hu, Yi-wen
    He, Qing
    Dai, Wei
    Xu, Cheng
    Chen, Li-jia
    Liu, Yan
    Nie, Guang
    HEPATOLOGY, 2009, 50 (04) : 494A - 494A
  • [40] High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40kd) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin
    Nelson, D.
    Pockros, P. J.
    Godofsky, E.
    Rodriguez-Torres, M.
    Everson, G.
    Fried, M.
    Ghalib, R.
    Harrison, S.
    Nyberg, L.
    Shiffman, M.
    Chan, A.
    Hill, G.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S371 - S371
12345